Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DPC (Diagnostic Products Corporation) takes US allergy test to the US:

This article was originally published in Clinica

Executive Summary

The US FDA has granted Diagnostic Products Corporation clearance to market its third generation IgE allergy test. The 510(k) approval for Immulite 2000 Allergen-Specific IgE has prompted the Los Angeles firm to rename the product Immulite 2000 Third Generation Allergen-Specific IgE, saying it is in a separate class to previous tests in terms of analytical performance. Run on the fully automated Immulite 2000 platform the assay offers a 0.1kU/L detection limit, which is 3.5 times lower than other allergen-specific tests, according to DPC. The company said that the new assay would be cost-effective enough for use by even very small laboratories.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel